Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 Trial
A Phase 3 trial presented at ESMO 2026 found that adding a personalized mRNA vaccine to Keytruda after melanoma surgery lowered the risk of the cancer returning. Overall survival has not yet differed significantly, and the full peer-reviewed paper is still to come.
FDA Approves Hibsago, a First-of-Its-Kind Hepatitis B Drug That Lets Some Patients Stop Treatment
The FDA has approved Hibsago (bepirovirsen), GSK's injectable antisense drug for chronic hepatitis B. In two phase 3 trials, about 19% of patients achieved a functional cure and could stop all treatment. The drug carries a boxed warning for liver reactions and low platelets.
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer, Opening a Path Around Surgery
The FDA has cleared GSK's immunotherapy Jemperli for a small, genetically defined group of patients with locally advanced rectal cancer. In trials, many avoided surgery, radiation and chemotherapy entirely, but the evidence comes from single-arm studies and longer follow-up is still required.